Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.
Avettand-Fenoel
Véronique
V
AP-HP, Laboratoire de Virologie, CHU Necker-Enfants Malades, Paris, France.
Flandre
Philippe
P
Chaix
Marie-Laure
ML
Ghosn
Jade
J
Delaugerre
Constance
C
Raffi
François
F
Ngovan
Philippe
P
Cohen-Codar
Isabelle
I
Delfraissy
Jean-François
JF
Rouzioux
Christine
C
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001773:Blood Cells / Q000821:virology*; D004279:DNA, Viral / Q000032:analysis* / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification*; D006801:Humans; D061466:Lopinavir; D016133:Polymerase Chain Reaction / Q000379:methods; D011744:Pyrimidinones / Q000627:therapeutic use*; D019438:Ritonavir / Q000627:therapeutic use*; D019562:Viral Load
D019380:Anti-HIV Agents; D004279:DNA, Viral; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir